Artificial Intelligence Technology in Neurodegenerative Diseases
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 67
Special Issue Editors
Interests: bioinformatics; genetics; biomarkers; clinical research; molecular biology
Special Issues, Collections and Topics in MDPI journals
Interests: bioinformatics; artificial intelligence; machine learning
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) is one of the world's largest public health problems, affecting an estimated 55 million people worldwide. Massive international research efforts have contributed to uncovering the molecular mechanisms underlying the onset and progression of Alzheimer's disease and developing therapeutic strategies for its treatment. Artificial intelligence technology (AI), especially machine learning (ML), has emerged as an indispensable tool for accelerating and improving AD prediction and diagnosis and drug discovery. However, the barriers to success for AI include challenges with data readiness, data imputation, data reduction, machine learning algorithms’ performance and efficiency, the discovery of new biomarkers (amyloid/tau/neurodegeneration (ATN), MRI, PET, metabolic, genome-wide association study, etc.), multi-omics data integration and classification, drug discovery, etc.
This Special Issue aims to bring together original research discussing and addressing these challenges in artificial intelligence technologies and their applications in neurodegenerative diseases. We invite submissions across the entire spectrum of this field. Topics of interest include, but are not limited to, the following:
- Data readiness for AI/ML for AD;
- Missing data imputation, feature selection and hyperparameter tuning for AD;
- AI/ML algorithm development for AD;
- Amyloid/tau/neurodegeneration (ATN) classification based on CSF biomarkers with AI/ML for AD;
- Multi-omics (proteomics, genomics, metabolics, imaging, environment, etc.) with AI/ML for AD;
- Drug discovery with AI/ML for AD.
Dr. Fan Zhang
Dr. Xiaogang Wu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- neurodegenerative diseases
- artificial intelligence
- machine learning
- data readiness for AI/ML
- feature elimination
- missing data imputation
- drug discovery
